Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
AAV product DS release-specific testing is a core quality attribute service for adeno-associated virus vectors, the most widely used viral vectors in gene therapy due to their non-pathogenicity, diverse tissue tropism, and long-term gene expression. To date, the FDA has approved multiple AAV gene therapies, with over 300 ongoing clinical trials. However, the inherently low packaging efficiency during AAV production results in empty capsid proportions of 50–90%, directly affecting product safety and efficacy. Creative Biogene provides one stop services from AAV drug substance release testing to IND/BLA submission data packages, with methods designed to align with the FDA Guidance for AAV Gene Therapy, USP <1047>, ICH Q5A(R2), and global regulatory requirements.
AAV production simultaneously generates full capsids, empty capsids, and partially filled capsids. Studies have shown that empty capsids can account for 50–90% of total AAV particles, depending on serotype, production system, and purification process. The FDA explicitly classifies these non functional viral particles as impurities because they impair dosing accuracy and induce non specific immunogenicity. Regulators require adequate characterization and monitoring of empty capsids.
Method 1: AEX HPLC (Anion Exchange High Performance Liquid Chromatography)
Separation based on subtle surface charge differences between full and empty capsids. Full capsids contain negatively charged genomic DNA, resulting in a different overall charge compared to empty capsids, leading to distinct elution behavior in a salt gradient. Under optimized chromatographic conditions and gradient elution, AEX HPLC can achieve baseline separation of full, empty, and partially filled capsids for many serotypes (separation resolution may be serotype dependent).
Method 2: TEM (Transmission Electron Microscopy)
TEM visualizes virus particles at high magnification after negative staining. Empty particles show low electron density in the core; full particles show high electron density. Quantitative electron microscopy (QuTEM), an enhanced TEM method, distinguishes full, partially filled, and empty AAV capsids based on internal density, showing high concordance with mass photometry and AUC data.
Method 3: AUC (Analytical Ultracentrifugation)
AUC separates AAV particles in a centrifugal field based on molecular weight and conformational differences. Full capsids sediment faster due to DNA loading; empty capsids sediment more slowly. Sedimentation velocity analytical ultracentrifugation (SV AUC) is the gold standard for AAV full/empty capsid quantitation, capable of quantifying all three capsid types simultaneously. AUC remains the gold standard for AAV characterization.
rcAAV (replication competent AAV) is formed by recombination of production raw material DNA during AAV manufacturing, resulting in complete, replication competent, potentially infectious virus like particles. rcAAV is a rare (<10⁻⁸) but hazardous event. rcAAV can reduce product efficacy or trigger adverse immune responses, and regulators mandate rcAAV contamination testing for clinical AAV products. However, traditional rcAAV detection methods have limitations in identifying recombination diversity and understanding how rcAAV is formed.
The detection method is based on forced amplification, because AAV is naturally replication defective, the method creates an artificial environment that allows any contaminating replication competent virus to proliferate. The AAV drug product is co infected with a helper virus (adenovirus type 5) into a permissive human cell line (typically HEK293 or engineered HeLaRC32). The helper virus provides all mechanisms required for viral replication. After serial passage (typically 3–4 weeks), the final lysate is analyzed by a sensitive molecular method (typically qPCR) to detect amplification of AAV genomes, indicating the presence of rcAAV.
AAV products typically report two titers – genome titer (by ddPCR/qPCR, quantifying viral genome copy number, reported as vg/mL) and infectious titer (by TCID50, quantifying infectious virus particles, reported as IU/mL). The ratio of genome to infectious titer reflects the proportion of functional virus particles relative to total particles and is a key indicator of AAV product potency and batch consistency.
Genome titer detection:
Infectious titer detection (TCID50):
The industry standard method for AAV infectious titer is the TCID50 assay, using a HeLa derived cell line stably expressing AAV serotype 2 rep and cap genes. Because AAV infection does not produce a cytopathic effect, rAAV TCID50 assays use qPCR or ddPCR as the endpoint method to quantify replicated viral genomes in inoculated wells, detecting infection events. Co infection with wild type adenovirus provides helper functions, and qPCR/ddPCR is used as the endpoint to detect infection events.
| Document | Key Requirement |
| FDA Guidance for AAV Gene Therapy | Identity, purity, potency, empty/full capsid, and replication competent virus testing required. Recommend determining full/empty particle ratio; no universal acceptance criteria; sponsors must justify acceptable levels based on clinical experience. |
| USP <1047> | Gene Therapy Products – comprehensive lifecycle quality management, including empty/full capsid testing strategies. |
| FDA CMC Guidance for CGT (2020) | Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy IND – risk based flexible framework with staged data submission; emphasizes functional bioactivity assays over surrogate potency indicators. |
| ICH Q5A(R2) | Viral Safety Evaluation – signed Nov 2023, adopted by FDA Jan 2024, EMA June 2024; rcAAV detection as part of viral safety evaluation. |
| ICH Q6B | Specifications framework – applicable to AAV purity, potency, and safety attributes. |
| BioPhorum Industry Consensus | Rejected proposal for minimum empty AAV capsid percentage specification; acceptance criteria should be based on clinical experience and batch to batch consistency. |
For a customized DS release testing strategy, method validation, or IND/BLA submission support for your AAV product, contact Creative Biogene’s technical team.
Q1: Is empty/full capsid testing mandatory for all AAV products?
A: Yes. The FDA explicitly classifies empty capsids as impurities and requires characterization and monitoring of empty/full capsid ratios. Although no universal acceptance criteria exist, sponsors must justify acceptable levels of empty and partially filled capsids in their products and minimize empty capsid levels through downstream purification steps. For IND submission, at least demonstrate similarity of impurity levels between IND enabling preclinical batches and clinical batches.
Q2: Which method should be chosen for empty/full capsid testing?
A: Choice depends on product stage, sample volume, and purpose. For routine release testing: AEX HPLC (high throughput, simple, low cost) – requires method comparability validation. For confirmatory/reference: AUC (gold standard). For visual verification: TEM/QuTEM (direct visualization, visualizes particle morphology and can identify unexpected structures or aggregates). For rapid screening: MP (low sample volume, fast). The FDA does not specify a mandatory method but requires a validated appropriate method with a reasonable interpretation of results. Creative Biogene recommends a multi platform orthogonal strategy with AEX HPLC as the primary method, TEM for visual verification, and AUC for confirmatory arbitration.
Q3: What is the impact of partially filled capsids on AAV product safety and efficacy?
A: Partially filled capsids contain truncated genomes or non target DNA (e.g., plasmid backbone, host DNA). The impact depends on the encapsidated content – truncated therapeutic transgene, transfection plasmid DNA, or host cell DNA. Partially filled capsids may: (1) reduce effective dose (fewer functional virus particles than total capsid count); (2) introduce risk of unintended gene expression (e.g., antibiotic resistance genes from plasmid backbone); (3) increase immunogenicity risk. Acceptable thresholds for partially filled capsids should be determined based on content identification and risk assessment.
Copyright © 2026 Creative Biogene. All rights reserved.